摘要
目的:探讨利舒康胶囊联合阿托伐他汀治疗高原地区原发性高脂血症患者的疗效。方法:将86例高原地区原发性高脂血症患者随机分为对照组和观察组,两组各43例。对照组给予阿托伐他汀治疗,观察组采用利舒康胶囊联合阿托伐他汀治疗。两组均持续治疗和观察8周,检测治疗前后血脂、丙二醛(MDA)、超氧化物歧化酶SOD、hs-CRP及IL-6水平变化,并评估临床疗效。结果:观察组患者治疗后,血浆TC、TG、LDL-C、MDA水平较对照组显著下降,HDL-C、SOD显著升高,差异均具有统计学意义(P <0. 05);两组患者治疗后炎症指标hs-CRP、IL-6均明显下降,但观察较对照组下降更为显著(P <0. 05);观察组治疗总有效率优于对照组(P <0. 05);两组治疗均无异常反应,安全性较好。结论:利舒康胶囊联合阿托伐他汀可有效调节高脂血症血脂水平和氧自由基代谢,减轻机体炎症损伤,疗效和安全性显著,显著优于阿托伐他汀单独治疗。
Objective:To investigate the therapeutic effect of Lishukang capsule combined with atorvastatin on patients with primary hyperlipidemia in plateau region.Methods:86 patients with primary hyperlipidemia in plateau region were randomly divided into the control group and the observation group,43 cases in each group.The patients in the control group were given atorvastatin,while the patients in the observation group were treated Lishukang capsule combined with atorvastatin.The patients in the both groups were continuously treated and observed for 8 weeks.The levels of serum lipid,malondialdehyde(MDA),superoxide dismutase(SOD),hs-CRP and IL-6 were measured before and after treatment,and the clinical efficacy was evaluated.Results:After treatment,the levels of TC,TG,LDL-C and MDA in the observation group significantly decreased,while HDL-C and SOD significantly increased,the differences were statistically significant(P<0.05).After treatment,the inflammatory indexes hs-CRP and IL-6 in both groups were significantly decreased,but the observation was more significant than that in the control group(P<0.05).The total effective rate in the observation group was better than that in the control group(P<0.05),there was no abnormal reaction in both groups,and the safety was better.Conclusion:Lishukang capsule combined with atorvastatin can effectively regulate blood lipid level and oxygen free radical metabolism in hyperlipidemia,alleviate inflammation injury of the body,has significant efficacy and safety,it is significantly better than atorvastatin alone.
作者
年蔚
廖宝霞
郗爱旗
NIAN Wei;LIAO Bao-xia;XI Ai-qi(Department of Geriatrics,Qinghai People′s Hospital,Xining 810007,Qinghai,China)
出处
《川北医学院学报》
CAS
2018年第6期852-854,共3页
Journal of North Sichuan Medical College
基金
青海省卫生和计划生育委员会医药卫生科研指导性计划项目(2017-wjzdx-17)
